title: Motavizumab, RSV, and subsequent wheezing - Authors' reply.
authors.affiliation: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA. Electronic address: klobrien@jhu.edu.
authors.forename: Katherine L
authors.initials: KL
authors.lastname: O'Brien
authors.affiliation: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA.
authors.forename: Amanda J
authors.initials: AJ
authors.lastname: Driscoll
authors.affiliation: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA.
authors.forename: Mathuram
authors.initials: M
authors.lastname: Santosham
authors.affiliation: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA.
authors.forename: Laura L
authors.initials: LL
authors.lastname: Hammitt
authors.affiliation: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA.
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Karron
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007223:Infant; D012135:Respiratory Sounds; D018357:Respiratory Syncytial Virus Infections
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C506968:motavizumab